Literature DB >> 20648400

Risk factors for urinary tract infections due to ciprofloxacin-resistant Escherichia coli in a tertiary care urology department in Switzerland.

Joëlle Nicoletti1, Stefan P Kuster, Tullio Sulser, Reinhard Zbinden, Christian Ruef, Bruno Ledergerber, Rainer Weber.   

Abstract

QUESTIONS UNDER STUDY: Monitoring of antimicrobial resistance is a key component of antibiotic stewardship programs. In 2007, a significantly higher resistance rate of Escherichia coli to ciprofloxacin was found at the Department of Urology, University Hospital Zurich, Switzerland, when compared to other hospital units. Thus, we aimed to determine the risk factors for this increased fluoroquinolone resistance in outpatients and inpatients with urinary tract infection (UTI) or colonisation with E. coli.
METHODS: We performed a cross sectional study including 275 patients of the Department of Urology in whom E. coli was isolated from urine or blood cultures between 01.01.2006 and 31.08.2007. Clinical data were collected from patients' records using a structured questionnaire. Multivariable analysis was performed for the detection of risk factors.
RESULTS: Ciprofloxacin-resistant E. coli was detected in 22% of patients. Risk factors for ciprofloxacin-resistant E. coli included prior use of fluoroquinolones (odds ratio [OR] (95% confidence intervals): 2.24 (1.08-4.62), p = 0.030), prior urinary tract catheterisation (OR: 2.41 (1.02-5.67), p = 0.044) and recurrent UTIs (OR: 2.26 (1.07-4.78), p = 0.032). 60.8% of all prescriptions in urinary tract infections were for fluoroquinolones, and this antibiotic class was the empiric antibiotic regimen of choice in 72.5% of all acute, uncomplicated, urinary tract infections.
CONCLUSIONS: The increasing prevalence of ciprofloxacin-resistant E. coli makes empiric therapy in UTIs with this agent questionable, especially in patients with one or several of the above mentioned risk factors. Due to the increasing resistance rate, continuous surveillance and susceptibility testing in individual patients, particularly with complicated UTIs, is indispensable for adequate therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20648400     DOI: 10.4414/smw.2010.13059

Source DB:  PubMed          Journal:  Swiss Med Wkly        ISSN: 0036-7672            Impact factor:   2.193


  6 in total

1.  Decreased susceptibility to commonly used antimicrobial agents in bacterial pathogens isolated from urinary tract infections in Rwanda: need for new antimicrobial guidelines.

Authors:  Claude Mambo Muvunyi; Florence Masaisa; Claude Bayingana; Léon Mutesa; André Musemakweri; Grégoire Muhirwa; Geert W Claeys
Journal:  Am J Trop Med Hyg       Date:  2011-06       Impact factor: 2.345

2.  Extended-spectrum β-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy.

Authors:  S Meier; R Weber; R Zbinden; C Ruef; B Hasse
Journal:  Infection       Date:  2011-06-25       Impact factor: 3.553

3.  Risk Factor Analysis of Ciprofloxacin-Resistant and Extended Spectrum Beta-Lactamases Pathogen-Induced Acute Bacterial Prostatitis in Korea.

Authors:  Young Lee; Dong Gi Lee; Sang Hyub Lee; Koo Han Yoo
Journal:  J Korean Med Sci       Date:  2016-11       Impact factor: 2.153

4.  Global fluoroquinolone resistance epidemiology and implictions for clinical use.

Authors:  Axel Dalhoff
Journal:  Interdiscip Perspect Infect Dis       Date:  2012-10-14

5.  Susceptibility pattern of uropathogens to ciprofloxacin at the Ghana police hospital.

Authors:  Daniel Kwame Afriyie; Martha Gyansa-Lutterodt; Seth Kwabena Amponsah; George Asare; Vanessa Wiredu; Edem Wormenor; Kwasi Agyei Bugyei
Journal:  Pan Afr Med J       Date:  2015-10-01

6.  Fluoroquinolone resistant bacterial isolates from the urinary tract among patients attending hospitals in Bushenyi District, Uganda.

Authors:  Martin Odoki; Adamu Almustapha Aliero; Julius Tibyangye; Josephat Nyabayo Maniga; Emmanuel Eilu; Ibrahim Ntulume; Eddie Wampande; Charles Drago Kato; Ezera Agwu; Joel Bazira
Journal:  Pan Afr Med J       Date:  2020-06-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.